LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
TARA
Protara Therapeutics, Inc.
There isn't enough reported data to score TARA yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
TARA Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
TARA's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
TARA PE Valuation
TARA has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
TARA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| -- | |
| -- | |
| Limited | |
| Moderate |
Analysts expect TARA's losses to grow, with revenue holding steady.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over TARA on earnings quality, reporting a profit while its opponent remains loss making.
TARA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.41 | -$0.21 |
| Q2 2026 | -$1.37 | +$0.02 |
| Q1 2026 | -$1.36 | +$0.13 |
| Q4 2025 | -$1.34 | +$0.83 |
| Q3 2025 | -$1.20 | +$1.62 |
| Q2 2025 | -$1.39 | +$1.80 |
| Q1 2025 | -$1.49 | +$2.25 |
| Q4 2024 | -$2.17 | +$1.40 |
TARA is still losing money, but far less than before: $1.41 per share over the past year, against $30.15 at its worst in late 2019.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
TARA Quarterly Revenue
TARA and LLY do not have enough comparable growth data to identify a winner.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the stronger cash trend. Its trailing FCF is up 259% versus its history, compared with TARA at down 78%.
TARA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$19.2M | -$6.7M |
| Q4 2025 | -$17M | -$7.7M |
| Q3 2025 | -$12.5M | -$4M |
| Q4 2024 | -$9.3M | -$608K |
| Q3 2024 | -$8.4M | -$1.8M |
| Q4 2023 | -$8.7M | -$3.7M |
| Q3 2023 | -$6.6M | -$1.2M |
| Q2 2023 | -$9.4M | -$4.3M |
TARA has burned cash in almost every quarter: −$61M over the past year, against −$41M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over TARA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
TARA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3% | +1.8M shares |
| 1 year | +49% | +20.6M shares |
| 3 years | +456% | +51.5M shares |
| 5 years | +460% | +51.6M shares |
| Available history | +12539% | +62.4M shares |
TARA has 63M diluted shares, up 49% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2024 | $76,000 |
| Q4 2023 | — |
| Q3 2023 | $27,000 |
| Q2 2023 | — |
| Q1 2023 | $64,000 |
| Q4 2022 | — |
| Q3 2022 | $18,000 |
| Q2 2022 | — |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
TARA Net Leverage
TARA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
TARA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 30.3 | Neutral |
| Stochastic | 12.5 | Oversold |
TARA's weekly RSI is 30 (neutral) and its Stochastic is 12 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
TARA PE vs Healthcare Sector
TARA has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over TARA on trend strength, trading above more of its moving averages.
TARA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.58 | 5.4% below |
| 20 week MA | $3.40 | 28% below |
| 50 week MA | $4.59 | 47% below |
| 100 week MA | $4.36 | 44% below |
| 200 week MA | $3.49 | 30% below |
TARA is in a downtrend: it's below all five of its weekly moving averages, and 30% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over TARA on returns for 2026, with the stronger performance.
TARA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $14.4 | $23.2 | +61% |
| 2021 | $23.2 | $6.90 | -70% |
| 2022 | $6.90 | $2.77 | -60% |
| 2023 | $2.77 | $1.88 | -32% |
| 2024 | $1.88 | $5.51 | +193% |
| 2025 | $5.51 | $5.55 | +0.7% |
| 2026 YTD | $5.55 | $2.44 | -56% |
TARA's yearly returns have swung widely, from +193% in 2024 to −70% in 2021. It's down 56% so far in 2026.